Company Kintor Pharmaceutical Limited

Equities

9939

KYG5273B1077

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Hong Kong S.E. Other stock markets 01:39:00 03/05/2024 pm IST			5-day change	1st Jan Change
1.21 ^HKD	+14.15%		+28.72%	-25.77%

22/04	Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint	CI
22/04	Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment	MT

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China. The Company is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The Company are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.

Number of employees: 225

Managers	Title	Age	Since
You Zhi Tong CEO	Chief Executive Officer	-	24/09/24
Ming Ming Cheung DFI	Director of Finance/CFO	47	01/21/01
Zhi Hua Ren CTO	Chief Tech/Sci/R&D Officer	-	01/20/01
Xiang Ni CTO	Chief Tech/Sci/R&D Officer	55	01/23/01
Qun Lu CTO	Chief Tech/Sci/R&D Officer	58	10/21/10
Liandong Ma CTO	Chief Tech/Sci/R&D Officer	-	-
Wai Chiu Wong IRC	Investor Relations Contact	69	17/22/17
Jiawen Han PRN	Corporate Officer/Principal	-	15/21/15
Guohao Zhou PRN	Corporate Officer/Principal	64	01/17/01
Mingming Yan SAM	Sales & Marketing	45	17/19/17

Members of the board	Title	Age	Since
Wei Peng Gao BRD	Director/Board Member	49	22/21/22
Cheng Wei Liu BRD	Director/Board Member	54	05/22/05
You Zhi Tong CEO	Chief Executive Officer	-	24/09/24
Min Xu BRD	Director/Board Member	59	12/19/12
Yeung Wai Yim BRD	Director/Board Member	60	12/19/12
Liang Tong BRD	Director/Board Member	60	27/20/27
Qun Lu CTO	Chief Tech/Sci/R&D Officer	58	10/21/10
Ge Qi Wei BRD	Director/Board Member	50	27/21/27
Xiang Ni CTO	Chief Tech/Sci/R&D Officer	55	01/23/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	447,499,600	359,636,431 ( 80.37 %)	0	80.37 %

Name	Equities	%	Valuation
You Zhi Tong 9.163 %	41,004,770	9.163 %	5 M $
Zhuhai State-Owned Assets Supervision & Admin. Commission 5.489 %	24,564,017	5.489 %	3 M $
Chuang Xin Guo 4.913 %	21,984,899	4.913 %	2 M $
Kiya Co. Ltd. 4.568 %	20,439,808	4.568 %	2 M $
LEGEND HOLDINGS CORPORATION 4.553 %	20,374,500	4.553 %	2 M $
Caitong Fund Management Co., Ltd. 0.6785 %	3,036,500	0.6785 %	333 651 $
Penghua Fund Management Co., Ltd. 0.2561 %	1,146,000	0.2561 %	125 922 $
Xiang Ni 0.0670 %	300,000	0.0670 %	32 964 $
Zhong Ou Asset Management Co., Ltd 0.0483 %	216,000	0.0483 %	23 734 $
Bosera Asset Management Co., Ltd. 0.0291 %	130,000	0.0291 %	14 284 $

Kintor Pharmaceutical Ltd.

Suzhou Industrial Park No. 20 Songbei Road

215123, Suzhou

http://www.kintor.com.cn

address Kintor Pharmaceutical Limited(9939)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.121 CNY

Average target price

13.21 CNY

Spread / Average Target

+1,078.42%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
KINTOR PHARMACEUTICAL LIMITED	-25.77%	60.69M
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	103B
REGENERON PHARMACEUTICALS, INC.	+8.96%	101B
ARGENX SE	+4.40%	23.07B
BIONTECH SE	-12.15%	22.23B
GENMAB A/S	-4.36%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.04%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.07B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.35B

Bio Therapeutic Drugs